Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 348
Gene Symbol: APOE
APOE
0.040 GeneticVariation disease BEFREE An additional 12 SNPs were associated with the PD phenotype at P ≤ 0.05 (APOE: rs405509, rs439401; TOMM40: rs8106922, and KIBRA: rs4320284, rs11740112, rs10040267, rs13171394, rs6555802, rs2241368, rs244904, rs6555805, and rs10475878). 30706571 2019
Entrez Id: 348
Gene Symbol: APOE
APOE
0.040 Biomarker disease BEFREE The goal of the study was to determine association between APOE Ɛ4 and gray matter changes in PD patients, with or without dementia. 27479921 2016
Entrez Id: 348
Gene Symbol: APOE
APOE
0.040 Biomarker disease BEFREE APOE genotyping was available for 107 PD patients (26 with and 81 without dementia) and 4,805 non-PD control subjects. 10746597 2000
Entrez Id: 348
Gene Symbol: APOE
APOE
0.040 GeneticVariation disease BEFREE Cognitive, neuropsychiatric, and motor features associated with apolipoprotein E ε4 allele in a sample of Bulgarian patients with late-onset Parkinson's disease. 24646656 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.010 Biomarker disease BEFREE In this case it is hypothesized that the ARs have now become hypertransactive, possibly coinciding with the estrogen resistance that is associated with PD tumors. 11768600 2001
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.010 GeneticVariation disease BEFREE Ribonuclease protection assay analysis of ASA mRNA transcripts and an investigation into the activity and lysosomal localization of protein expressed by an ASA expression construct containing the N350S variant indicated that both the N350S and polyadenylation defects play a role in biochemically defining the ASA-PD phenotype. 9668161 1998
Entrez Id: 171023
Gene Symbol: ASXL1
ASXL1
0.020 Biomarker disease BEFREE The aim of this study was to evaluate the relationship between all MDS-UPDRS components and HRQoL in a representative international cohort of PD patients. 29625875 2018
Entrez Id: 171023
Gene Symbol: ASXL1
ASXL1
0.020 Biomarker disease BEFREE a cohort study, comparing 10 PD patients with severe speech impairment (MDS-UPDRS item 3.1 ≥ 3) with 10 PD patients with mild speech impairment (MDS-UPDRS item 3.1 ≤ 2), all submitted to STN-DBS. 31060986 2019
Entrez Id: 23400
Gene Symbol: ATP13A2
ATP13A2
0.020 Biomarker disease BEFREE In conclusion, we found no consistent evidence for an association between ATP13A2 and late-onset PD. 19097176 2009
Entrez Id: 23400
Gene Symbol: ATP13A2
ATP13A2
0.020 GeneticVariation disease BEFREE The present review will describe the parkinsonian phenotypes emerging from the new Mendelian genes which have been linked to PD (such as PARK9 and PARK14), the associated dystonia-parkinsonism disorders (such as the syndromes of neurodegeneration with brain iron accumulation) and the emerging data on heterozygous variants of genes which could influence the risk to develop PD and the PD phenotypes (like PD associated with glucose cerebrosidase mutations). 20817231 2010
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.510 Biomarker disease CTD_human
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.510 Biomarker disease GENOMICS_ENGLAND
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.510 GeneticVariation disease BEFREE We found two patients in one familial PD (FPD) family (1.5%) and two sporadic PD patients (0.5%) with expanded CAG repeats in the ATXN2 locus, four patients in two FPD families (3%) and another three sporadic PD patients (0.8%) in the MJD1 locus. 19672991 2009
Entrez Id: 4287
Gene Symbol: ATXN3
ATXN3
0.110 SusceptibilityMutation disease CLINVAR
Entrez Id: 4287
Gene Symbol: ATXN3
ATXN3
0.110 Biomarker disease BEFREE To investigate the prevalence and clinical feature(s) of Parkinson's disease (PD) patients with expanded (ATXN2 and MJD1) genes of spinocerebellar ataxia type 2 and 3 (SCA2 and SCA3/MJD) in a mainland Chinese population, CAG triplet repeat expansions of (SCA2 and SCA3/MJD) genes (ATXN2 and MJD1) were analyzed in a cohort of 452 PD patients, including 386 sporadic and 66 familial forms. 19672991 2009
Entrez Id: 6315
Gene Symbol: ATXN8OS
ATXN8OS
0.300 Biomarker disease CTD_human
Entrez Id: 551
Gene Symbol: AVP
AVP
0.010 Biomarker disease BEFREE The aim of this study was to assess if copeptin concentrations in plasma and dialysate were related to peritoneal transport parameters and residual renal function (RRF) in incident PD patients. 31187425 2019
Entrez Id: 8705
Gene Symbol: B3GALT4
B3GALT4
0.010 AlteredExpression disease BEFREE Reduced levels of brain gangliosides GD1a, GD1b, GT1b and to a lesser extent GM1 have been found in substantia nigra (SN) from Parkinson's disease (PD) patients, along with decreased gene expression for key enzymes (B3Galt4, St3gal2) involved in synthesis of these gangliosides. 30611881 2019
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.010 AlteredExpression disease BEFREE Serum BChE activity decreased in PD patients compared with healthy controls. 28840123 2017
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.040 Biomarker disease BEFREE In this review, we attempted to explore the role of BDNF and its associated pathways in susceptibility to Schizophrenia (Scz), Alzheimer's (AD), and Parkinson's (PD) diseases. 29512462 2018
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.040 AlteredExpression disease BEFREE The observation of reduced level of BDNF in the substantia nigra (SN) of Parkinson's disease (PD) patients suggests its important role in neuron protection in PD pathogenesis. 29030221 2018
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.040 Biomarker disease BEFREE Five studies compared BDNF in serum of PD patients versus healthy controls (HC) and 3 studies provided BDNF levels in sera of non-depressed and depressed PD patients (NDPD and DPD). 30296429 2019
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.040 GeneticVariation disease BEFREE The studied BDNF polymorphism was not associated with cognitive status in PD patients. 24394906 2014
Entrez Id: 100653365
Gene Symbol: BED
BED
0.010 Biomarker disease BEFREE More specifically, PD significantly differed from BN and BED in natural course of illness (g = .40-.54), and PD significantly differed from AN in treatment outcome (g = .27), with PD characterized by a better prognosis. 28691846 2017
Entrez Id: 140683
Gene Symbol: BPIFA2
BPIFA2
0.020 Biomarker disease BEFREE Free-water-corrected fractional anisotropy values were greater for PSP patents than for controls and PD patients. 28714593 2017